Pristina Bright
With over a decade of contrast mammography leadership worldwide, GE HealthCare’s contrast enhancing mammography (CEM) is a game changer in breast diagnostic imaging and biopsy care.
GE HealthCare pioneered this technology in 2010 and is associated with over 200 publications that demonstrate its clinical performance. GE HealthCare’s CEM combines the morphologic and density information similar to a conventional mammogram and the functional vascular information of a breast MRI1. It presents an opportunity to create and implement a more streamlined workflow to help diagnosis breast cancer early. In addition to increasing patient access, our CEM offering boasts high levels of sensitivity and specificity, allowing for the detection of lesions that would otherwise go undetected2,3,4. To ensure your practice can fully leverage the combined power of GE HealthCare contrast mammography solutions, we introduce Pristina Bright our comprehensive CEM package with complete support, from training to service, for your successful implementation.
Over a decade of contrast mammography leadership
Our Pristina Bright comprehensive contrast-enhanced mammography package bundles:
CEM educational course
Learn moreReferences
1. 510(k) K172404.
2. Compared to without contrast.
3. Sung JS, et al. Performance of Dual-Energy Contrast-enhanced Digital Mammography for Screening Women at Increased Risk of Breast Cancer. Radiology. 2019 Oct;293(1):81-88.
4. Sorin V, et al. Contrast-Enhanced Spectral Mammography in Women With Intermediate Breast Cancer Risk and Dense Breasts. AJR Am J Roentgenol. 2018 Nov;211(5):W267-W274. 5. Data on file. GE HealthCare 2020.
5. 510(k) K211215. Reader study performed by 3 MQSA qualified radiologists on 50 clinical images, comparing SenoBright HD with NIRA to current version.
2. Compared to without contrast.
3. Sung JS, et al. Performance of Dual-Energy Contrast-enhanced Digital Mammography for Screening Women at Increased Risk of Breast Cancer. Radiology. 2019 Oct;293(1):81-88.
4. Sorin V, et al. Contrast-Enhanced Spectral Mammography in Women With Intermediate Breast Cancer Risk and Dense Breasts. AJR Am J Roentgenol. 2018 Nov;211(5):W267-W274. 5. Data on file. GE HealthCare 2020.
5. 510(k) K211215. Reader study performed by 3 MQSA qualified radiologists on 50 clinical images, comparing SenoBright HD with NIRA to current version.